Related Experiment Video
Updated: Dec 23, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Bonnie Ky1,2, Douglas L Mann3
1Department of Medicine, Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract:
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.
Insights
This review provides essential information on COVID-19 treatments for cardiovascular and cardio-oncology physicians. It covers emerging cardiovascular epidemiology and the rationale behind ongoing clinical trials for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).
Area of Science:
- Cardiology
- Infectious Diseases
- Oncology
Background:
- The COVID-19 pandemic spurred numerous clinical trials for SARS-CoV-2.
- Many treatments under investigation are repurposed drugs with historical applications.
Purpose of the Study:
- To equip cardiovascular and cardio-oncology physicians with foundational knowledge on COVID-19.
- To explain the cardiovascular epidemiology and biological rationale of ongoing COVID-19 therapeutic trials.
Main Methods:
- Review of existing literature on COVID-19 treatments.
- Analysis of cardiovascular implications and trial rationales.
Main Results:
- Identification of repurposed therapeutic agents for COVID-19.
- Summary of emerging cardiovascular epidemiology related to COVID-19.
Conclusions:
- Understanding repurposed treatments is crucial for cardiovascular and cardio-oncology specialists.
- This knowledge supports informed patient care and clinical trial interpretation for COVID-19.
More Related Videos
02:47Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Preclinical Development: Overview
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease I: Introduction